Intrarosa (Prasterone)

Prasterone is converted locally within the vaginal epithelium to estrogen and androgen metabolites. These hormones bind to their respective receptors, stimulating cell proliferation, increasing glycogen storage, and enhancing vascularization, which together improve tissue elasticity and lubrication.

The prescribed dose of Intrarosa is determined by the treating physician based on the patient’s clinical condition. The product is supplied as a 6.5 mg vaginal insert, and the healthcare professional will provide specific dosing instructions.

Safety of Intrarosa in pregnancy has not been established, and it is generally avoided in pregnant women. Information on use during breastfeeding is limited; clinicians should consider potential risks and benefits before prescribing to nursing mothers.

To order Intrarosa, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details and import documentation.

Intrarosa delivers a local androgen and estrogen effect directly to vaginal tissues, whereas systemic hormone replacement therapy provides broader hormonal exposure. Compared with non‑hormonal lubricants, Intrarosa addresses underlying tissue changes, offering longer‑term improvement in dyspareunia.

Intrarosa should be stored at room temperature, kept in its original packaging, and protected from moisture and excessive heat. Do not expose the inserts to direct sunlight or humidity to maintain product integrity.

Intrarosa is administered as a vaginal insert. The patient inserts the 6.5 mg device into the vagina, typically once daily, following the specific instructions provided by the prescribing healthcare professional.

Serious risks include significant vaginal bleeding, allergic reactions such as rash or swelling, and systemic hormonal effects that could affect hormone‑sensitive conditions. Patients should report any severe or unexpected symptoms to their healthcare provider promptly.

Intrarosa should not be used by women who are pregnant, have known hypersensitivity to prasterone or any excipients, or have active estrogen‑dependent malignancies without careful medical supervision. Contraindications are determined by the prescribing clinician.